Oliver Zuehlke - Bayer AG Member of the Supervisory Board
| BAYRYDelisted Stock | USD 16.86 0.86 5.37% |
Executive
Mr. Oliver Zuehlke was Independent Vice Chairman of the Supervisory Board, Employee Representative of Bayer Aktiengesellschaft since July 2015. He was Member of the Supervisory Board and Employee Representative at the Company from April 27, 2007. He is Member of the Presidial CommitteeMediation Committee, the Audit Committee and the Innovation Committee at the Company. He joined Bayer AG in Leverkusen, Germany, in 1985 and trained as a chemical production technician. During his training, in 1988, he became a member of the body representing young employees and apprentices. He chaired this body from 1990 to 1994. He was elected a fulltime member of the Works Council at the Leverkusen site in 1994 and was Deputy Chairman from 2002 to 2010. Since then, he has also been a member of the Economics Committee of Bayer AG. In 2009, he completed a distance learning course on human resources management. Between 2010 and 2015 he was Chairman of the Works Council at the Leverkusen site and also held various functions in the German Mining, Chemical and Power Workers Union . He was a member of the District Executive, the Regional Executive, the federal industrial group for the chemical industry, and the advisory board. From 2009 to 2015 Zuehlke was Chairman of the Bayer European Forum. In 2014 he became Member of the Supervisory Board of Bayer Pharma AG. Since 2015 he was Chairman of the Central Works Council of Bayer AG. since 2015.
| Age | 49 |
| Tenure | 9 years |
| Phone | 49 214 30 1 |
| Web | https://www.bayer.com |
Bayer AG Management Efficiency
The company has return on total asset (ROA) of 0.0576 % which means that it generated a profit of $0.0576 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.13 %, meaning that it generated $0.13 on every $100 dollars invested by stockholders. Bayer AG's management efficiency ratios could be used to measure how well Bayer AG manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 35.55 B in total debt with debt to equity ratio (D/E) of 1.08, which is about average as compared to similar companies. Bayer AG PK has a current ratio of 1.14, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Bayer AG until it has trouble settling it off, either with new capital or with free cash flow. So, Bayer AG's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bayer AG PK sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bayer to invest in growth at high rates of return. When we think about Bayer AG's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Samir Shah | Novartis AG ADR | N/A | |
| Peter Kornicker | Novartis AG ADR | N/A | |
| Flavius MD | Gilead Sciences | N/A | |
| Stephan Feldhaus | Roche Holding Ltd | 56 | |
| Catherine Owen | Bristol Myers Squibb | 54 | |
| Paul Arkel | Novartis AG ADR | N/A | |
| Karl Mahler | Roche Holding Ltd | N/A | |
| Linda MD | Novartis AG ADR | 61 | |
| Madeleine Roach | Sanofi ADR | 40 | |
| Rudolf Ertl | Gilead Sciences | 78 | |
| Ahn Poole | Bristol Myers Squibb | 49 | |
| Etienne Jousseaume | Novartis AG ADR | N/A | |
| Urs Jaisli | Roche Holding Ltd | 62 | |
| Steven Baert | Novartis AG ADR | 45 | |
| Gideon Blumenthal | Merck Company | N/A | |
| David Epstein | Novartis AG ADR | 53 | |
| Alan Hippe | Roche Holding Ltd | 56 | |
| Pierre Chancel | Sanofi ADR | 67 | |
| Thomas Larsen | AstraZeneca PLC ADR | N/A | |
| Jeffrey George | Novartis AG ADR | 41 | |
| Giovanni MD | Bristol Myers Squibb | 59 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0576 |
Bayer AG PK Leadership Team
Elected by the shareholders, the Bayer AG's board of directors comprises two types of representatives: Bayer AG inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bayer. The board's role is to monitor Bayer AG's management team and ensure that shareholders' interests are well served. Bayer AG's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bayer AG's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Oliver Maier, Head Relations | ||
| Heiko Schipper, Member of the Management Board, Head of the Consumer Health Division | ||
| Thomas Fischer, Member of the Supervisory Board | ||
| Marijn Dekkers, Chairman of Management Board and CEO | ||
| Helmut Panke, Member of the Supervisory Board | ||
| Reiner Hoffmann, Member of the Supervisory Board | ||
| Sue Rataj, Member of the Supervisory Board | ||
| Petra ReinboldKnape, Member of the Supervisory Board | ||
| Dieter Weinand, Member of the Management Board and Head of the Pharmaceuticals Division, North America Region | ||
| Werner Baumann, Chief Strategy and Portfolio Officer and Member of Management Board | ||
| Sarena Lin, Labor Officer | ||
| Simone BagelTrah, Member of the Supervisory Board | ||
| Michael SchmidtKiessling, Member of the Supervisory Board | ||
| ErnstLudwig Winnacker, Member of the Supervisory Board | ||
| Colleen Goggins, Member of the Supervisory Board | ||
| Heinz Webers, Member of the Supervisory Board | ||
| Johanna Faber, Member of the Supervisory Board | ||
| Frank Loellgen, Member of the Supervisory Board | ||
| Andre Broich, Member of the Supervisory Board | ||
| Liam Condon, Member of Management Board and CEO of Bayer Cropscience | ||
| Rodrigo Santos, Member Division | ||
| Patrick Thomas, CEO, Bayer MaterialScience | ||
| Yueksel Karaaslan, Member of the Supervisory Board | ||
| Erica Mann, Member of the Management Board, Head of the Consumer Health Division | ||
| Norbert Bischofberger, Member of the Supervisory Board | ||
| Hartmut Klusik, Member of the Management Board, Director of Human Resources, Technology & Sustainability | ||
| Michael Koenig, Member of the Management Board responsible for Human Resources | ||
| Thomas Win, Vice Chairman of the Supervisory Board | ||
| Jennifer Brendelto, Vice President - Communications of the Consumer Health Division | ||
| Heike Hausfeld, Member of the Supervisory Board | ||
| Peter Hausmann, Member of the Supervisory Board | ||
| Detlef Rennings, Member of the Supervisory Board | ||
| Werner Wenning, Chairman of the Supervisory Board | ||
| Michael Preuss, Gov Communications | ||
| Kemal Malik, Member of Management Board, Chief Medical Officer of Bayer Healthcare and Head of Global Devel. - Bayer Healthcare | ||
| Petra Kronen, Member of the Supervisory Board | ||
| Oliver Zuehlke, Member of the Supervisory Board | ||
| Thomas Elsner, Member of the Supervisory Board | ||
| Alexander Rosar, Head of Investor Relations | ||
| Wolfgang Nickl, CFO, Member of the Management Board | ||
| Paul Achleitner, Member of the Supervisory Board | ||
| Klaus Sturany, Independent Member of the Supervisory Board | ||
| Stefan Oelrich, Member of the Management Board, Head of the Pharmaceuticals Division | ||
| Thomas Ebeling, Member of the Supervisory Board | ||
| Johannes Dietsch, CFO and Member of Management Board | ||
| Gabriel Harnier, Patents Law | ||
| Norbert Winkeljohann, Independent Member of the Supervisory Board | ||
| Clemens Boersig, Member of the Supervisory Board | ||
| Juergen Beunink, Interim Head of Investor Relations | ||
| Otmar Wiestler, Member of the Supervisory Board | ||
| Sabine Schaab, Member of the Supervisory Board | ||
| BerndPeter Bier, Head Taxes | ||
| Wolfgang Plischke, Member of the Supervisory Board |
Bayer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bayer AG a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0576 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 87.41 B | ||||
| Shares Outstanding | 3.93 B | ||||
| Shares Owned By Institutions | 0.10 % | ||||
| Price To Earning | 12.46 X | ||||
| Price To Book | 1.36 X | ||||
| Price To Sales | 1.02 X |
Pair Trading with Bayer AG
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bayer AG position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bayer AG will appreciate offsetting losses from the drop in the long position's value.Moving against Bayer Pink Sheet
| 0.74 | VAXX | Vaxxinity Financial Report 14th of May 2024 | PairCorr |
| 0.73 | DRTS | Alpha Tau Medical Financial Report 28th of May 2024 | PairCorr |
| 0.63 | VERV | Verve Therapeutics Earnings Call This Week | PairCorr |
| 0.63 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.59 | VCNX | Vaccinex | PairCorr |
The ability to find closely correlated positions to Bayer AG could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bayer AG when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bayer AG - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bayer AG PK to buy it.
The correlation of Bayer AG is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bayer AG moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bayer AG PK moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bayer AG can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Bayer Pink Sheet
If you are still planning to invest in Bayer AG PK check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bayer AG's history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stocks Directory Find actively traded stocks across global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |